KCNA10抗体;KCNA10 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P13370(KCNA10 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The KCNA10 antibody targets the potassium voltage-gated channel subfamily A member 10 (KCNA10), a protein encoded by the KCNA10 gene. This channel is part of the Shaker-related voltage-gated potassium (Kv) channel family, which regulates cellular excitability and repolarization in excitable tissues. KCNA10 is primarily expressed in the kidney, vascular smooth muscle, and brain, where it contributes to potassium ion transport, membrane potential stabilization, and vascular tone modulation. Its role in renal electrolyte balance and blood pressure regulation has drawn interest in hypertension and cardiovascular research.

KCNA10 antibodies are widely used in research to detect and quantify protein expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of KCNA10 has been implicated in pathological conditions, including hypertension, atherosclerosis, and renal dysfunction. In cancer, altered KCNA10 expression may influence tumor progression through mechanisms linked to cell proliferation and apoptosis. Additionally, autoantibodies against KCNA10 have been studied in autoimmune disorders affecting ion channel function.

As a research tool, the KCNA10 antibody aids in elucidating the channel’s physiological roles and its potential as a therapeutic target. However, its specificity and validation across experimental models remain critical considerations to ensure accurate data interpretation. Ongoing studies continue to explore its diagnostic and therapeutic relevance in channelopathies and metabolic diseases.